Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Alnylam Pharmaceuticals on Friday, setting a price target of $145, which is approximately 3.80% above the present share price of $139.69.
Shu expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$2.09 for the second quarter of 2021.
The current consensus among 15 TipRanks analysts is for a Moderate Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $171.67.
The analysts price targets range from a high of $235 to a low of $90.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $163.56 million and a net profit of -$194.22 million. The company's market cap is $16.39 billion.
According to TipRanks.com, Berenberg Bank analyst Zhiqiang Shu is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 18.8% and a 50.00% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.